FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199617009> ?p ?o ?g. }

• W3199617009 endingPage "289" @default.
• W3199617009 startingPage "289" @default.
• W3199617009 abstract "289 Background: Among mNSCLC patients positive for EGFR mutation (EGFRm), first-line (1L) treatment with an EGFR TKI is recommended for best outcomes. This study describes real-world treatment patterns of mNSCLC patients using EGFR TKIs in the 1L setting, including osimertinib, the most recently approved EGFR TKI for 1L use. Methods: Patients with ≥1 claim for an EGFR TKI (1st generation [1G]: gefitinib, erlotinib; 2nd generation [2G]: afatinib, dacomitinib; 3rd generation: osimertinib) from January 1, 2015 – April 30, 2020 were identified in IQVIA’s prescription (LRx) and medical claims (Dx) databases; first date of EGFR TKI was the index date. Patients had 12-month baseline period before index, variable follow-up after index, ≥1 lung cancer diagnosis on index or in baseline, and earliest metastatic cancer diagnosis on or 90 days before index. Kaplan-Meier analysis was used to estimate 1L treatment duration, where treatment discontinuation was defined as >60-day gap in medication supply of the index EGFR TKI. Patient characteristics and treatment patterns were stratified by 1L EGFR TKI. Results: Overall, 2,505 mNSCLC patients received 1L EGFR TKI (982 osimertinib, 1,060 1G, 463 2G). Median ages were 66-69 years, 64.6-67.1% were female, and 32.4-38.9% had central nervous system metastases on or before index. Most patients were commercially insured (50.8-62.9%), 35.3-45.9% had Medicare, and 0.6-3.3% had other payer types. Nearly all patients had 1L EGFR TKI monotherapy (97.6-99.7%). 1L treatment duration was longer for osimertinib compared to 1G or 2G EGFR TKI (median months, 17.8, 8.7, 10.5 respectively). 2L treatment was observed in 32.5% of 1G and 36.3% of 2G EGFR TKI cohorts. Osimertinib monotherapy, chemotherapy, and immunotherapy (monotherapy or combined with chemotherapy) accounted for 58.3%, 7.0%, and 4.3% of 2L treatments after 1L 1G EGFR TKI, respectively, and 60.7%, 4.2%, and 4.8% of 2L treatments after 1L 2G EGFR TKI. Conclusions: In real-world practice, 1L treatment duration is longer with osimertinib compared with other EGFR TKIs. Future studies with longer follow-up are recommended to understand treatment patterns after progression on EGFR TKIs, mainly osimertinib, given its recent approval." @default.
• W3199617009 created "2021-09-27" @default.
• W3199617009 creator A5025682014 @default.
• W3199617009 creator A5038508387 @default.
• W3199617009 creator A5058911447 @default.
• W3199617009 creator A5068747041 @default.
• W3199617009 creator A5086351627 @default.
• W3199617009 date "2021-10-01" @default.
• W3199617009 modified "2023-10-16" @default.
• W3199617009 title "Real-world treatment patterns of metastatic non-small cell lung cancer (mNSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)." @default.
• W3199617009 doi "https://doi.org/10.1200/jco.2020.39.28_suppl.289" @default.
• W3199617009 hasPublicationYear "2021" @default.
• W3199617009 type Work @default.
• W3199617009 sameAs 3199617009 @default.
• W3199617009 citedByCount "0" @default.
• W3199617009 crossrefType "journal-article" @default.
• W3199617009 hasAuthorship W3199617009A5025682014 @default.
• W3199617009 hasAuthorship W3199617009A5038508387 @default.
• W3199617009 hasAuthorship W3199617009A5058911447 @default.
• W3199617009 hasAuthorship W3199617009A5068747041 @default.
• W3199617009 hasAuthorship W3199617009A5086351627 @default.
• W3199617009 hasConcept C121608353 @default.
• W3199617009 hasConcept C126322002 @default.
• W3199617009 hasConcept C143998085 @default.
• W3199617009 hasConcept C2776256026 @default.
• W3199617009 hasConcept C2777626846 @default.
• W3199617009 hasConcept C2778087573 @default.
• W3199617009 hasConcept C2778715236 @default.
• W3199617009 hasConcept C2779438470 @default.
• W3199617009 hasConcept C2780580887 @default.
• W3199617009 hasConcept C2780586478 @default.
• W3199617009 hasConcept C71924100 @default.
• W3199617009 hasConceptScore W3199617009C121608353 @default.
• W3199617009 hasConceptScore W3199617009C126322002 @default.
• W3199617009 hasConceptScore W3199617009C143998085 @default.
• W3199617009 hasConceptScore W3199617009C2776256026 @default.
• W3199617009 hasConceptScore W3199617009C2777626846 @default.
• W3199617009 hasConceptScore W3199617009C2778087573 @default.
• W3199617009 hasConceptScore W3199617009C2778715236 @default.
• W3199617009 hasConceptScore W3199617009C2779438470 @default.
• W3199617009 hasConceptScore W3199617009C2780580887 @default.
• W3199617009 hasConceptScore W3199617009C2780586478 @default.
• W3199617009 hasConceptScore W3199617009C71924100 @default.
• W3199617009 hasIssue "28_suppl" @default.
• W3199617009 hasLocation W31996170091 @default.
• W3199617009 hasOpenAccess W3199617009 @default.
• W3199617009 hasPrimaryLocation W31996170091 @default.
• W3199617009 hasRelatedWork W2503069423 @default.
• W3199617009 hasRelatedWork W2822334320 @default.
• W3199617009 hasRelatedWork W2888534976 @default.
• W3199617009 hasRelatedWork W2979271184 @default.
• W3199617009 hasRelatedWork W3000070469 @default.
• W3199617009 hasRelatedWork W3082721204 @default.
• W3199617009 hasRelatedWork W3175282903 @default.
• W3199617009 hasRelatedWork W4281690819 @default.
• W3199617009 hasRelatedWork W4307234767 @default.
• W3199617009 hasRelatedWork W4324344390 @default.
• W3199617009 hasVolume "39" @default.
• W3199617009 isParatext "false" @default.
• W3199617009 isRetracted "false" @default.
• W3199617009 magId "3199617009" @default.
• W3199617009 workType "article" @default.